New drug duo tested in Tough-to-Treat blood cancers
NCT ID NCT04231851
Summary
This study is testing whether combining two drugs, CPX-351 and glasdegib, is safe and effective for adults with specific types of acute myeloid leukemia (AML) who have not yet received treatment. The main goal is to see how many patients are still in remission and event-free six months after starting the treatment. Researchers will also closely monitor side effects and overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOGENOUS LEUKEMIA (AML) DUE TO THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, 92868, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.